EP1379889A1 - Determination de la fonction d'entree arterielle en irm de contraste dynamique - Google Patents

Determination de la fonction d'entree arterielle en irm de contraste dynamique

Info

Publication number
EP1379889A1
EP1379889A1 EP02728696A EP02728696A EP1379889A1 EP 1379889 A1 EP1379889 A1 EP 1379889A1 EP 02728696 A EP02728696 A EP 02728696A EP 02728696 A EP02728696 A EP 02728696A EP 1379889 A1 EP1379889 A1 EP 1379889A1
Authority
EP
European Patent Office
Prior art keywords
voxel
time course
signal
nmr
studies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02728696A
Other languages
German (de)
English (en)
Inventor
Timothy J. Carroll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/888,973 external-priority patent/US6546275B2/en
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of EP1379889A1 publication Critical patent/EP1379889A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
    • G01R33/281—Means for the use of in vitro contrast agents

Definitions

  • the field of the invention is magnetic resonance imaging (MRI).and particularly the measurement of hemodynamic parameters such as cerebral blood flow (CBF) and cerebral blood volume (CBV).
  • MRI magnetic resonance imaging
  • CBF cerebral blood flow
  • CBV cerebral blood volume
  • Ischemic stroke is one of the leading causes of death and disability.
  • An important treatment for a stroke patient is the use of so-called "thrombolytic” agents, or “clot busting” drugs which have been shown to break tip blood clots that are the source of the stroke. These drugs must be administered within three to six hours of the ischemic event and considerable risk of cerebral hemorrhage is associated with their use.
  • Hemodynamically weighted MR perfusion images of cerebral blood flow may be acquired and used in combination with diffusion-weighted (DWI) MR images to delineate regions of viable brain parenchyma that are at risk of further infarction.
  • the DWI MR image shows ischemic regions where brain cells have died, and the CBF image shows regions with reduced blood flow which indicates at risk tissue.
  • the size of the "ischemic penumbra" surrounding ischemic tissues is a critical component in evaluating treatment options.
  • the hemodynamically weighted images must be acquired and produced expeditiously.
  • the risks associated with thrombolytic agents increases with time and the prevailing opinion is that such agents should not be used more than 3 to 6 hours after the ischemic event.
  • Diffusion-weighted MR images can be acquired and reconstructed in a matter of minutes using MRI systems as described, for example, in U.S. Pat. Nos. 5,492,123; 6,078,176; 5,671 ,741 and 5,488,297. The same cannot be said of current methods for producing CBF, MR images.
  • the resulting NMR signal intensity versus time curves can be converted into contrast agent concentration-time curves.
  • CBF cerebral blood flow
  • CBV cerebral blood volume
  • AIF arterial input function
  • the present invention relates to the measurement of hemodynamic parameters such as cerebral blood flow, and more particularly, to a method which enables the rapid and automatic production of MR images that more accurately indicate the value of hemodynamic parameters throughout a selected region of interest.
  • the present invention is a method for automatically identifying an arterial voxel in a data set acquired during a dynamic contrast-enhanced MR study and calculating therefrom the arterial input function (AIF). Hemodynamic parameters are calculated using the acquired data set and this calculated AIF.
  • a general object of the invention is to shorten the time needed to produce hemodynamic parameter images. No manual steps are required after acquisition of the data set during the dynamic study. As a result, images can be produced promptly which enable the physician to assess the risks of clinical actions.
  • Another object of the invention is to provide a more accurate AIF. This is accomplished by first identifying that portion of the dynamic study data set which indicates first passage of the contrast bolus through the region of interest. Within this limited data set, the signal produced by each voxel in the region of interest during first passage is examined to select the one voxel which best exhibits arterial blood flow characteristics. AIF is calculated using the NMR signal produced by this voxel.
  • FIG. 1 is a block diagram of an NMR system which employs the present invention
  • Fig. 2 is an electrical block diagram of the transceiver which forms part of the NMR system of Fig. 1 ;
  • Fig. 3 is a graphic representation of the EPI pulse sequence used to practice the present invention on the NMR system of Fig. 1 ;
  • Fig. 4 is a pictorial representation of the NMR image data acquired with the pulse sequence of Fig. 3;
  • Fig. 5 is a graphic representation of a typical time course voxel signal S(t) produced from data in Fig. 4;
  • Fig. 6 is a flow chart which illustrates the steps used to practice a preferred embodiment of the invention.
  • Fig. 7 is a flow chart which illustrates a preferred method for calculating AIF for use in the procedure of Fig. 6;
  • Fig. 8 is a graphic representation of an exemplary arterial input function. DESCRIPTION OF THE PREFERRED EMBODIMENT
  • FIG. 1 there is shown the major components of a preferred NMR system which incorporates the present invention and which is sold by the General Electric Company under the trademark "SIGNA".
  • the operation of the system is controlled from an operator console 100 which includes a console processor 101 that scans a keyboard 102 and receives inputs from a human operator through a control panel 103 and a plasma display/touch screen 104.
  • the console processor 101 communicates through a communications link 116 with an applications interface module 117 in a separate computer system 107.
  • an operator controls the production and display of images by an image processor 106 in the computer system 107, which connects directly to a video display 118 on the console 100 through a video cable 105.
  • the computer system 107 is formed about a backplane bus which conforms with the VME standards, and it includes a number of modules which communicate with each other through this backplane.
  • these include a CPU module 108 that controls the WE backplane, and an SCSI interface module 109 that connects the computer system 107 through a bus 110 to a set of peripheral devices, including disk storage 111 and tape drive 112.
  • the computer system 107 also includes a memory module 113, known in the art as a frame buffer for storing image data arrays, and a serial interface module 114 that links the computer system 107 through a high speed serial link 115 to a system interface module 120 located in a separate system control cabinet 122.
  • the system control 122 includes a series of modules which are connected together by a common backplane 118.
  • the backplane 118 is comprised of a number of bus structures, including a bus structure which is controlled by a CPU module 119.
  • the serial interface module 120 connects this backplane 118 to the high speed serial link 115, and pulse generator module 121 connects the backplane 118 to the operator console 100 through a serial link 125. It is through this link 125 that the system control 122 receives commands from the operator which indicate the scan sequence that is to be performed.
  • the pulse generator module 121 operates the system components to carry out the desired scan sequence. It produces data which indicates the timing, strength and shape of the RF pulses which are to be produced, and the timing of and length of the data acquisition window.
  • the pulse generator module 121 also connects through serial link 126 to a set of gradient amplifiers 127, and it conveys data thereto which indicates the timing and shape of the gradient pulses that are to be produced during the scan.
  • the pulse generator module 121 also receives patient data through a serial link 128 from a physiological acquisition controller 129.
  • the physiological acquisition control 129 can receive a signal from a number of different sensors connected to the patient.
  • the pulse generator module 121 may receive ECG signals from electrodes or respiratory signals from a bellows and produce pulses for the pulse generator module 121 that synchronizes the scan with the patient's cardiac cycle or respiratory cycle.
  • the pulse generator module 121 connects through a serial link 132 to scan room interface circuit 133 which receives signals at inputs 135 from various sensors associated with the position and condition of the patient and the magnet system. It is also through the scan room interface circuit 133 that a patient positioning system 134 receives commands which move the patient cradle and transport the patient to the desired position for the scan.
  • the gradient waveforms produced by the pulse generator module 121 are applied to a gradient amplifier system 127 comprised of G x , G y and G z amplifiers 136, 137 and 138, respectively. Each amplifier 136, 137 and 138 is utilized to excite a corresponding gradient coil in an assembly generally designated 139.
  • the gradient coil assembly 139 forms part of a magnet assembly 155 which includes a polarizing magnet 140 that produces a 1.5 Tesla polarizing field that extends horizontally through a bore.
  • the gradient coils 139 encircle the bore, and when energized, they generate magnetic fields In the same direction as the main polarizing magnetic field, but with gradients G x , G y and G z directed in the orthogonal x-, y- and z-axis directions of a Cartesian coordinate system.
  • the gradient magnetic fields are utilized to encode spatial information into the NMR signals emanating from the patient being scanned.
  • a circular cylindrical whole-body RF coil 152 Located within the bore 142 is a circular cylindrical whole-body RF coil 152.
  • This coil 152 produces a circularly polarized RF field in response to RF pulses provided by a transceiver module 150 in the system control cabinet 122. These pulses are amplified by an RF amplifier 151 and coupled to the RF coil 152 by a transmit/receive switch 154 which forms an integral part of the RF coil assembly. Waveforms and control signals are provided by the pulse generator module 121 and utilized by the transceiver module 150 for RF carrier modulation and mode control.
  • the resulting NMR signals radiated by the excited nuclei in the patient may be sensed by the same RF coil 152 and coupled through the transmit/receive switch 154 to a preamplifier 153.
  • the amplified NMR signals are demodulated, filtered, and digitized in the receiver section of the transceiver 150.
  • the transmit/receive switch 154 is controlled by a signal from the pulse generator module 121 to electrically connect the RIF amplifier 151 to the coil 152 during the transmit mode and to connect the preamplifier 153 during the receive mode.
  • the transmit receive switch 154 also enables a separate local RF head coil to be used in the transmit and receive mode to improve the signal-to-noise ratio of the received NMR signals.
  • the main magnet assembly 141 In addition to supporting the polarizing magnet 140 and the gradient coils 139 and RF coil 152, the main magnet assembly 141 also supports a set of shim coils 156 associated with the main magnet 140 and used to correct inhomogeneities in the polarizing magnet field.
  • the main power supply 157 is utilized to bring the polarizing field produced by the superconductive main magnet 140 to the proper operating strength and is then removed.
  • the NMR signals picked up by the RF coil are digitized by the transceiver module 150 and transferred to a memory module 160 which is also part of the system control 122.
  • an array processor 161 operates to Fourier transform the data into an array of image data.
  • This image data is conveyed through the serial link 115 to the computer system 107 where it is stored in the disk memory 111.
  • this image data may be archived on the tape drive 112, or it may be further processed by the image processor 106 and conveyed to the operator console 100 and presented on the video display 118 as will be described in more detail hereinafter.
  • the transceiver 150 includes components which produce the RIF excitation field 131 through power amplifier 151 at a coil 152A and components which receive the resulting NMR signal induced in a coil 152B.
  • the coils 152A and B may be a single whole-body coil, but a local RF coil specially designed for the head may also be used.
  • the base, or carrier, frequency of the RF excitation field is produced under control of a frequency synthesizer 200 which receives a set of digital signals (CF) through the backplane 118 from the CPU module 119 and pulse generator module 121. These digital signals indicate the frequency and phase of the RF carrier signal which is produced at an output 201.
  • CF digital signals
  • the commanded RF carrier is applied to a modulator and up converter 202 where its amplitude is modulated in response to a signal R(t) also received through the backplane 118 from the pulse generator module 121.
  • the signal R(t) defines the envelope, and therefore the bandwidth, of the RF excitation pulse to be produced. It is produced in the module 121 by sequentially reading out a series of stored digital values that represent the; desired envelope. These stored digital values may, in turn, be changed from the operator console 100 to enable any desired RF pulse envelope to be produced.
  • the modulator and up converter 202 produces an RF pulse at the desired Larmor frequency at an output 205.
  • the magnitude of the RF excitation pulse output through line 205 is attenuated by an exciter attenuator circuit 206 which receives a digital command, TA, from the backplane 118.
  • the attenuated RF excitation pulses are applied to the power amplifier 151 that drives the RF coil 152A.
  • the NMR signal produced by the subject is picked up by the receiver coil 152B and applied through the preamplifier 153 to the input of a receiver attenuator 207.
  • the receiver attenuator 207 further amplifies the NMR signal and this is attenuated by an amount determined by a digital attenuation signal (RA) received from the backplane 118.
  • RA digital attenuation signal
  • the receive attenuator 207 is also turned on and off by a signal from the pulse generator module 121 such that it is not overloaded during RF excitation.
  • the received NMR signal is at or around the Larmor frequency, which in the preferred embodiment is around 63.86 MHz for 1.5 Tesla.
  • This high frequency signal is down converted in a two step process by a down converter 208 which first mixes the NMR signal with the carrier signal on line 201 and then mixes the resulting difference signal with the 2.5 MHz reference signal on line 204.
  • the resulting down converted NMR signal on line 212 has a maximum bandwidth of 125 kHz and it is centered at a frequency of 187.5 kHz.
  • the down converted NMR signal is applied to the input of an analog-to-digital (A D) converter 209 which samples and digitizes the analog signal at a rate of 250 kHz.
  • a D analog-to-digital
  • the output of the A/D converter 209 is applied to a digital detector and signal processor 210 which produce 16-bit in-phase (1) values and 16-bit quadrature (Q) values corresponding to the received digital signal.
  • the resulting stream of digitized I and Q values of the received NMR signal is output through backplane 118 to the memory module 160 where they are employed to reconstruct an image.
  • both the modulator and up converter 202 in the exciter section and the down converter 208 in the receiver section are operated with common signals. More particularly, the carrier signal at the output 201 of the frequency synthesizer 200 and the 2.5 MHz reference signal at the output 204 of the reference frequency generator 203 are employed in both frequency conversion processes. Phase consistency is thus maintained and phase changes in the detected NMR signal accurately indicate phase changes produced by the excited spins.
  • the 2.5 MHz reference signal as well as 5, 10 and 60 MHz reference signals are produced by the reference frequency generator 203 from a common 20 MHz master clock signal. The latter three reference signals are employed by the frequency synthesizer 200 to produce the carrier signal on output 201.
  • U.S. Pat. No. 4,992,736 which is incorporated herein by reference.
  • the EPI pulse sequence employed in the preferred embodiment of the invention is illustrated in Fig. 3.
  • a 60° RF excitation pulse 250 is applied in the presence of a G z slice select gradient pulse 251 to produce transverse magnetization in a slice through the brain.
  • the excited spins are rephased by a negative lobe 252 on the slice select gradient G z and then a time interval elapses before the readout sequence begins.
  • a total of 64 separate NMR echo signals, indicated generally at 253, are acquired during the EPI pulse sequence.
  • TE desired echo time
  • the NMR echo signals 253 are gradient recalled echo's produced by the application of an oscillating G x readout gradient field 255.
  • the readout sequence is started with a negative readout gradient lobe 256 and the echo signals 253 are produced as the readout gradient oscillates between positive and negative values.
  • a total of 128 samples are taken of each NMR echo signal 253 during each readout gradient pulse 255.
  • the successive 64 NMR echo signals 253 are separately phase encoded by a series of G y phase encoding gradient pulses 258.
  • Subsequent phase encoding pulses 258 occur as the readout gradient pulses 255 switch polarity, and they step the phase encoding monotonically upward through k y space.
  • the EPI pulse sequence is typically repeated to acquire time course NMR data for 14 slice images over the period during which a contrast agent bolus makes a first pass through the brain.
  • the acquired NMR data is processed in the conventional manner to produce an NMR image data set of images for each of the 14 slices.
  • a two dimensional Fourier transformation is performed by the array processor 161 (Fig. 1) and the resulting NMR image data set is stored in the disk 111 for further processing by the image processor 106 according to the present invention.
  • this NMR image data set for one slice is organized as a set of 128x64 element 2D arrays 300 in which each element stores the magnitude of the NMR signal from one voxel in the scanned slice. While each array 300 is a "snap shot" of the brain slice at a particular moment in time during the time course study, the NMR image data set may also be viewed as a single 128x64x36 3D array 301 in which the third dimension is time.
  • time course NMR image data for one voxel in the array 301 is referred to herein as a time course voxel study.
  • a time course voxel study One such -study is illustrated in Fig. 4 by the dashed line 302.
  • Each time course voxel study 302 indicates the magnitude of the NMR signal at a voxel in the image slice over the time course study and a typical signal S(t) for a voxel is shown in Fig 5.
  • the signal S(t) is characterized by a noisy pre-contrast phase 305 in which the signal varies within a limited range, followed by a sudden drop in the signal at bolus arrival 307.
  • the signal S(t) recovers as the contrast bolus passes through the voxel and then it drops again when the contrast bolus recirculates at 309 and enters the voxel for a second pass.
  • the present invention is employed in a procedure which starts with the injection of a contrast agent into the subject as indicated at process block 350.
  • the time course NMR image data is then acquired at process block 352 as described above. Because it is usually necessary to throw out the first 5 or 6 seconds of acquired data in the study, it is common practice to start the data acquisition step 352 10 to 15 seconds prior to the contrast injection step 350. This insures that there is adequate NMR data acquired prior to contrast arrival.
  • the data acquisition step 352 typically requires from one to two minutes to complete. After the images are reconstructed as described above, the average brightness of all acquired brain voxels is calculated for each image frame as indicated at block 354.
  • N V0XELS total number of brain voxels
  • N x , N y , N z , total number of voxels along the respective x, y and z axes
  • the resulting signal S AVG (t) indicates the average signal magnitude of all the voxels in the stack of 2D images acquired at time t.
  • the next step is to calculate the mean value of this average brain signal SAVG(t) during the pre-contrast phase 305 of the study. This is done by selecting a set of pre-contrast image frames and calculating the mean value So thereof as follows:
  • N is the total number of pre-contrast images used.
  • So is then calculated as follows:
  • contrast arrival time is determined as indicated at process block 358. This is accomplished by first calculating the number of standard deviations a the average brain signal SAVG(t)varies from the pre-contrast mean brain signal So as a function of time (t):
  • the standard deviation signal N ⁇ (t) is also used to determine a contrast arrival time (t a ).
  • the signal N ⁇ (t) is examined as described above and the image frame at which the average brain signal S AVG (t) drops more than ten a below the pre-contrast brain signal average So (i.e., N ⁇ (t) >-10) is determined.
  • the contrast arrival time ta is set to the previous image frame time, that is, the image frame time Just prior to the image frame in which N ⁇ (t) drops below -10.
  • the next step as indicated at process block 360 is to calculate the arterial input function (AIF). This is accomplished automatically using the above information.
  • AIF arterial input function
  • TE is the echo time of the MRI pulse sequence used to acquire the NMR data
  • S 0 (x,y,z) is the mean value of the voxel signal S(x,y,z,t) during the pre-contrast phase of the study as calculated using the above equation (2).
  • the end of the pre contrast phase is marked by the image frame at time t ⁇ as determined above.
  • peak refers to the time limits which define the first passage of the contrast bolus. These time limits are determined when calculating the AIF as will be described in detail below and they essentially define the time limits of the peak in the arterial signal during the first pass of the contrast agent through the brain.
  • the cerebral blood volume CBV(x,y,z) can now be calculated for each voxel as follows:
  • peak refers to the time limits which define the first passage of the contrast bolus as described above and the denominator is the area defined by the peak in the arterial input function (AIF) as shown at 368 in Fig. 8.
  • AIF arterial input function
  • An alternative method of calculating the CBF is to perform a mathematical deconvolution of each voxels concentration versus time curve using the AIF as has been described by L. Ostergarrd et al "High Resolution Measurement of Cerebral Blood Flow Using I ntravascular Tracer Bolus Passages. Part 1 : Mathematical Approach and Statistical Analysis", Magnetic Resonance in Medicine, 36:715-725 (1996).
  • Images may now be produced from the calculated hemodynamic parameters as indicated at process block 372.
  • the MTT, CBV and CBF values calculated in equations (6), (7) and (8) provide the magnitudes of these respective hemodynamic parameters at each voxel within the x, y, and z extent of the acquired NMR data. These magnitudes are used to control the brightness of the corresponding pixels in any chosen image. For example, transverse 2D images through the brain with pixel brightness modulated by the CBF (x,y,z) values will show re&ns with less blood flow as darker than regions with more blood flow. Since the brain is substantially symmetrical about its center, physicians typically look for differences in brightness in corresponding regions in the left and right sides of the brain. A region on one side of the brain which is significantly darker than the corresponding region on the other side of the brain is at risk of further infarction.
  • the AIF is calculated automatically from the acquired NMR image data.
  • the general objective of this automated procedure is to locate the image voxel which has a signal S(t) that best represents the signal produced by arterial blood flow into the brain.
  • the first step in this automated process at block 380 calculates the mean value of each voxel signal S(x,y,z,t) during the pre-contrast phase of the study:
  • N is the number of image frames during the pre-contrast phase which ends at frame t 0 .
  • the next step is to remove from consideration those voxels which are clearly not arteries. As indicated at process block 382, this includes filtering out voxels whose mean pre-contrast signal S 0 (x,y,z) from equation (9) does not exceed a preset threshold value. These are typically voxels that are located in air outside the patient's head.
  • the next step is to remove from consideration voxels that do not demonstrate a significant signal drop after the completion of the pre-contrast phase as indicated at process block 384. This is accomplished by examining each voxel signal S(x,y,z,t) during the four successive time frames starting with the frame at the above-determined whole-brain contrast arrival time t a . All voxels having less than five standard deviation loss (i.e., 5 * ⁇ (x,y,z)) in signal strength from its pre-contrast mean (i.e., S 0 (x,y,z)) signal strength is removed from consideration.
  • 5 * ⁇ (x,y,z) in signal strength from its pre-contrast mean
  • each voxel signal S(x,y,z,t) drops five deviations below its pre-contrast mean is marked as the contrast arrival time (t arr ) for that voxel.
  • the next step is to filter out venous voxels. These are characterized by late contrast arrival times (t arr ) and they are removed if their arrival time is more than two seconds later than the earliest recorded voxel arrival time (t arr ) among the remaining candidate voxels.
  • the final step in locating an arterial voxel is to examine the magnitude of the signal loss during contrast arrival for each of the remaining candidate voxels. As indicated at process block 388 this is accomplished by summing the signal loss in each candidate voxel in four consecutive image frames
  • AS(x,y,z) ⁇ S ⁇ x,y,z,t) - S 0 (x,y,z).
  • the voxel with the maximum drop in signal strength ⁇ S is selected as the AIF voxel as indicated at process block 390. Its signal S(x,y,z,t) is selected as the function AIF(t) for use in the above- described calculations.
  • the "peak" in the AIF(t) function is determined by calculating its derivative as indicated at process block 392. This is done by calculating the change in signal for the AIF voxel from one image frame to the next. The time at which the AIF derivative changes from negative to positive is identified as the peak time. After the first pass of the bolus of contrast agent through the AIF voxel, a second passage of the same bolus is observed shortly thereafter. This recirculation effect must be removed from AIF(t) during the above calculations and this is accomplished by locating the point in the AIF(t) signal when the recirculation peak arrives.

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La présente invention concerne une étude des temps d'absorption pendant une IRM de contraste donnant des images faisant apparaître des paramètres d'hémodynamique concernant notamment le flux de sang cérébral (CBF), le volume de sang cérébral (CBV), et le temps moyen de transit (MTT). L'invention permet de produire automatiquement une fonction d'entrée artérielle nécessaire pour la mesure quantitative de ces paramètres d'hémodynamique.
EP02728696A 2001-04-20 2002-04-10 Determination de la fonction d'entree arterielle en irm de contraste dynamique Ceased EP1379889A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28529301P 2001-04-20 2001-04-20
US285293P 2001-04-20
US888973 2001-06-25
US09/888,973 US6546275B2 (en) 2001-06-25 2001-06-25 Determination of the arterial input function in dynamic contrast-enhanced MRI
PCT/US2002/011012 WO2002086530A1 (fr) 2001-04-20 2002-04-10 Determination de la fonction d'entree arterielle en irm de contraste dynamique

Publications (1)

Publication Number Publication Date
EP1379889A1 true EP1379889A1 (fr) 2004-01-14

Family

ID=26963117

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02728696A Ceased EP1379889A1 (fr) 2001-04-20 2002-04-10 Determination de la fonction d'entree arterielle en irm de contraste dynamique

Country Status (2)

Country Link
EP (1) EP1379889A1 (fr)
WO (1) WO2002086530A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8320647B2 (en) 2007-11-20 2012-11-27 Olea Medical Method and system for processing multiple series of biological images obtained from a patient
CN102238906B (zh) * 2008-10-07 2013-11-06 奥森医疗科技有限公司 急性中风的诊断
BRPI1007717A2 (pt) 2009-04-13 2017-01-31 Koninl Philips Electronics Nv sistema de processamento de imagem e método para determinar as informações de referência plausíveis dos dados de imagem
US20120203122A1 (en) 2011-02-09 2012-08-09 Opher Kinrot Devices and methods for monitoring cerebral hemodynamic conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6073042A (en) * 1997-09-25 2000-06-06 Siemens Medical Systems, Inc. Display of three-dimensional MRA images in which arteries can be distinguished from veins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02086530A1 *

Also Published As

Publication number Publication date
WO2002086530A1 (fr) 2002-10-31

Similar Documents

Publication Publication Date Title
US6546275B2 (en) Determination of the arterial input function in dynamic contrast-enhanced MRI
US6968225B2 (en) Real-time localization, monitoring, triggering and acquisition of 3D MRI
US5565777A (en) Method/apparatus for NMR imaging using an imaging scheme sensitive to inhomogeneity and a scheme insensitive to inhomogeneity in a single imaging step
US6144874A (en) Respiratory gating method for MR imaging
EP1145029B1 (fr) Reconstruction guidee par contraste en angiographie par resonance magnetique a contrastes ameliores
US6292684B1 (en) Respiratory displacement and velocity measurement using navigator MRI echo signals
US6493569B2 (en) Method and apparatus using post contrast-enhanced steady-state free precession in MR imaging
JP3512482B2 (ja) 磁気共鳴映像装置
US7755355B2 (en) Method and system of enhanced phase suppression for phase-contrast MR imaging
EP1055935A2 (fr) Imagerie du coeur en tranches multiples par résonance magnétique avec déclenchement sensible à la respiration
US20020156366A1 (en) Realtime MR scan prescription using physiological information
US8588889B2 (en) Method and apparatus for breath-held MR data acquisition using interleaved acquisition
US5422576A (en) Magnetic resonance angiography using fast spin echo pulse sequence
JP2004000611A (ja) 移動式寝台と対話式制御を備えた全身ｍｒｉスキャン法
US7570985B2 (en) Method and apparatus for magnetic resonance imaging using contrast agent
US20050073305A1 (en) Magnetic resonance imaging using direct, continuous real-time imaging for motion compensation
EP1227332B1 (fr) Procédé pour l'acquisition d'images par résonance magnétique avec une haute résolution de temps et sans empêcher la respiration
US8315450B2 (en) Method and system for display of medical image data
US6201986B1 (en) Synchronized K-space sampling in magnetic resonance angiography
US8509874B2 (en) Method for non-contrast enhanced pulmonary vein magnetic resonance imaging
CN112394311B (zh) 具有改进的导航器的mri系统
US8838204B2 (en) System and method for phase contrast imaging with improved efficiency
JP4349647B2 (ja) 磁気共鳴イメージング装置
EP1379889A1 (fr) Determination de la fonction d'entree arterielle en irm de contraste dynamique
WO2008132686A1 (fr) Quantification de paramètres caractéristiques de résonance magnétique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20070420

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18R Application refused

Effective date: 20120327

18W Application withdrawn

Effective date: 20120327